FDA Publishes Article Critical of Vilazodone Data

It has been over a year now since the approval of vilazodone (Viibryd). As you may recall from our review of the drug in TCPR April 2011, vilazodone is an SSRI with partial agonism at the 5HT1A receptor.

Current Subscribers

Purchase a subscription

To view the full content, you need to purchase a subscription.